L. Mercer, A. Green, J. Galloway, R. Davies, M. Lunt et al., The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register, Annals of the Rheumatic Diseases, vol.71, issue.6, pp.869-874, 2011.
DOI : 10.1136/annrheumdis-2011-200622

J. Askling, C. Fored, L. Brandt, E. Baecklund, L. Bertilsson et al., Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists, Annals of the Rheumatic Diseases, vol.64, issue.10, pp.1421-1426, 2005.
DOI : 10.1136/ard.2004.033993

L. Mellemkjaer, M. Linet, G. Gridley, M. Frisch, H. Møller et al., Rheumatoid arthritis and cancer risk, European Journal of Cancer, vol.32, issue.10, pp.1753-1757, 1996.
DOI : 10.1016/0959-8049(96)00210-9

X. Mariette, M. Matucci-cerinic, K. Pavelka, P. Taylor, R. Van-vollenhoven et al., Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis, Annals of the Rheumatic Diseases, vol.70, issue.11, pp.1895-1904, 2011.
DOI : 10.1136/ard.2010.149419

X. Mariette, V. Reynolds, A. Emery, and P. , Updated meta-analysis of non-melanoma skin cancer rates reported from prospective observational studies in patients treated with tumour necrosis factor inhibitors, Annals of the Rheumatic Diseases, vol.71, issue.12, p.23014259, 2012.
DOI : 10.1136/annrheumdis-2012-202478

F. Wolfe and K. Michaud, Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study, Arthritis & Rheumatism, vol.92, issue.9, pp.2886-2895, 2007.
DOI : 10.1002/art.22864

J. Askling, K. Fahrbach, B. Nordstrom, S. Ross, C. Schmid et al., Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data, Pharmacoepidemiology and Drug Safety, vol.32, issue.10, pp.119-130, 2011.
DOI : 10.1002/pds.2046

J. Askling, . Behalf-of-the, . Artis-study, and . Group, Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS Registry, Ann Rheum Dis, vol.68, p.423, 1998.

M. Dougados, M. Soubrier, A. Antunez, P. Balint, A. Balsa et al., Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA), Annals of the Rheumatic Diseases, vol.71, issue.1, pp.62-68, 2014.
DOI : 10.1136/annrheumdis-2013-204223

T. Pham, H. Bachelez, J. Berthelot, J. Blacher, Y. Bouhnik et al., TNF alpha antagonist therapy and safety monitoring, Joint Bone Spine, vol.78, issue.111, pp.15-185, 2011.
DOI : 10.1016/S1297-319X(11)70001-X
URL : https://hal.archives-ouvertes.fr/hal-00618537

F. Grange, A. Woronoff, R. Bera, M. Colomb, B. Lavole et al., Efficacy of a general practitioner training campaign for early detection of melanoma in France, British Journal of Dermatology, vol.157, issue.5 Suppl. 1, pp.123-129, 2014.
DOI : 10.1111/bjd.12585

A. Geller, S. Swetter, S. Oliveria, S. Dusza, and A. Halpern, Reducing mortality in individuals at high risk for advanced melanoma through education and screening, Journal of the American Academy of Dermatology, vol.65, issue.5, pp.587-594, 2011.
DOI : 10.1016/j.jaad.2011.05.045